Skip to main content

MAGENTIQ EYE Ltd.

Category: AI in Healthcare

An AI-powered decision support system that provides real-time detection of polyps during colonoscopy procedures to assist gastroenterologists. MAGENTIQ EYE Ltd. was founded in 2014. The company is led by Dror Zur. Based in Haifa, Israel. Team size: 11-50. Total funding raised: Undisclosed amount. Latest round: Series A. Key investors include aMoon, Tal Capital, Allied Investments, Gefen Capital, Dr. Shmuel Cabilly, Jonathan Kolber.

Founded
2014
Headquarters
Haifa, Israel
Team size
11-50
Total funding
Undisclosed amount

Value proposition

To improve the accuracy and effectiveness of colonoscopies by significantly increasing the detection rate of pre-cancerous polyps (adenomas), thereby reducing the risk of colorectal cancer for patients and enhancing the standard of care.

Products and solutions

MAGENTIQ-COLO™

Unique value

The core innovation is a real-time AI that acts as a 'second eye' for physicians during live colonoscopies. Unlike post-procedure analysis, it integrates directly into the clinical workflow, drawing attention to suspicious lesions that might otherwise be missed. Its superior performance has been validated in clinical studies, showing a 26% increase in Adenoma Detection Rate (ADR).

Target customer

Gastroenterologists, hospitals, and outpatient clinics that perform colonoscopy procedures.

Industries served

Healthcare, Medical Devices, Gastroenterology

Technology advantage

The key technological advantage is its advanced AI algorithm that utilizes deep learning and computer vision for real-time video analysis. The main business advantages are its regulatory approvals (FDA 510(k) clearance and CE Mark), which represent a significant barrier to entry, and a strategic distribution partnership with PENTAX Medical for the U.S. market.

How they differentiate

MAGENTIQ EYE's core product, the MAGENTIQ-COLO™, is designed to be compatible with all major colonoscopy video systems, offering broader integration possibilities for hospitals and clinics. This contrasts with some competitors whose systems are tied to their own hardware. The company emphasizes its superior real-time polyp detection rates, which have been validated in clinical studies, and its user-friendly interface that seamlessly integrates into existing workflows.

Main competitors

Medtronic (GI Genius), Iterative Health, Olympus

Key partnerships

PENTAX of America, Inc. (a HOYA Group Company) for distribution in the U.S. market., aMoon, a global Healthtech & Life Sciences VC fund, as the lead investor in their Series A funding round.

Notable customers

PENTAX Medical (Distribution Partner for the U.S. Market)

Major milestones

FDA clearance for the MAGENTIQ-COLO™ system., CE Mark approval for the MAGENTIQ-COLO™ system in Europe., Successful completion of a multi-center clinical study demonstrating a significant increase in adenoma detection rate (ADR)., Establishment of a distribution partnership with PENTAX Medical to commercialize the technology in the United States., Secured Series A funding to fuel commercial expansion and further R&D.

Growth metrics

Specific growth metrics are not publicly disclosed. However, the company is actively expanding its commercial presence in the US and European markets.

Market positioning

MAGENTIQ EYE is positioning itself as a leading innovator in AI-powered decision support for gastroenterology, focusing on improving the quality and efficiency of colonoscopies. The company aims to set a new standard in the early detection of colorectal cancer by providing a universally compatible, high-performance AI solution.

Geographic focus

The company's primary geographic focus for commercialization is the United States and Europe. The recent Series A funding is intended to support and accelerate this expansion.

Patents and IP

Information on specific patents is not publicly detailed in general sources, but the company's technology is based on proprietary AI, deep learning, and computer vision algorithms.

About Dror Zur

Founder and CEO of MAGENTIQ EYE with over two decades of experience leading R&D in computer vision, machine learning, and signal processing. Previously held R&D leadership roles at companies like Mediguide (acquired by St. Jude Medical) and superDimension (acquired by Covidien). Holds a Ph.D. in Electrical Engineering from Tel Aviv University.

Official website: